Safety and Immunogenicity of the Oral, Whole Cell/Recombinant B Subunit Cholera Vaccine in North American Volunteers

Jose L. Sanchez, Andrew F. Trofa, David N. Taylor, Robert A. Kuschner, Robert F. DeFraites, Stephen C. Craig, M. Raghava Rao, John D. Clemens, Ann Mari Svennerholm, Jerald C. Sadoff, Jan Holmgren, Jose L. Sanchez, Andrew F. Trofa, David N. Taylor, Robert A. Kuschner, Robert F. DeFraites, Stephen C. Craig, M. Raghava Rao, John D. Clemens, Ann Mari SvennerholmJerald C. Sadoff, Jan Holmgren, Jose L. Sanchez, Andrew F. Trofa, David N. Taylor, Robert A. Kuschner, Robert F. DeFraites, Stephen C. Craig, M. Raghava Rao, John D. Clemens, Ann Mari Svennerholm, Jerald C. Sadoff, Jan Holmgren

Research output: Contribution to journalArticle

Abstract

A newly formulated, oral, inactivated whole cell plus recombinant B subunit (WC/rBS) cholera vaccine was evaluated in US military personnel. In the first study, 74 subjects were given two doses 14 days apart. In the second study, 186 subjects were randomized into four groups; two groups received vaccine with either full (4 g) or half (2 g) strength bicarbonate buffer, and two groups received either full or half strength buffer without vaccine. Mild gastrointestinal symptoms were associated with full buffer (P =.02) but not with the vaccine. In the first study, 36% of all subjects and 55% with low prevaccination titers <1:40) had a ⩾2-fold rise in vibriocidal antibody level; >80% of subjects developed a 4-fold rise in anti-cholera toxin (CT) titers. Postvaccination IgA and IgG anti-CT titers were ∼1.5-fold higher among persons receiving full strength buffer (P =.05). The WC/rBS vaccine is safe and immunogenic in North Americans, although some mild gastrointestinal symptoms occur with the high concentration ofbuffer necessary to protect the B subunit from gastric acid denaturation. Prior immunity to cholera conferred by parenteral vaccine decreased vibriocidal antibody response.

Original languageEnglish (US)
Pages (from-to)1446-1449
Number of pages4
JournalJournal of Infectious Diseases
Volume167
Issue number6
DOIs
StatePublished - Jun 1993

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Safety and Immunogenicity of the Oral, Whole Cell/Recombinant B Subunit Cholera Vaccine in North American Volunteers'. Together they form a unique fingerprint.

  • Cite this

    Sanchez, J. L., Trofa, A. F., Taylor, D. N., Kuschner, R. A., DeFraites, R. F., Craig, S. C., Rao, M. R., Clemens, J. D., Svennerholm, A. M., Sadoff, J. C., Holmgren, J., Sanchez, J. L., Trofa, A. F., Taylor, D. N., Kuschner, R. A., DeFraites, R. F., Craig, S. C., Rao, M. R., Clemens, J. D., ... Holmgren, J. (1993). Safety and Immunogenicity of the Oral, Whole Cell/Recombinant B Subunit Cholera Vaccine in North American Volunteers. Journal of Infectious Diseases, 167(6), 1446-1449. https://doi.org/10.1093/infdis/167.6.1446